Transforming Spine Surgery Through Personalized Solutions

Our mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The Carlsmed aprevo® personalized surgery platform is designed to improve the standard of care for spine surgery one patient at a time.

Our Core Values

We are committed to three guiding principles:

PATIENT-OBSESSED.
DO WHAT IS RIGHT.
ACHIEVE TOGETHER.

Leadership Team

Mike Cordonnier

Chief Executive Officer

Jodi Allen

Senior Vice President, People and Culture

Sharon Schulzki

Chief Clinical Officer

Niall Casey

Chief Intellectual Property Officer

Shariq Hussain

Chief Technology Officer

Leo Greenstein

Chief Financial Officer

Tim Murawski

Senior Vice President Global Business Development

Scott Durall

Chief Commercial Officer

Board of Directors

Mike is the co-founder and serves as Chief Executive Officer and President of Carlsmed, he also serves as Chairman of the Board of Directors.

Mike has over two decades of experience successfully leading teams in introducing groundbreaking medical technologies. He possesses extensive operational expertise in both private and public companies, having contributed to the success of organizations such as NuVasive, Ellipse Technologies, Zimmer Biomet, Orchid Orthopedics, and X-Spine Systems.

Mike holds a Bachelor of Science degree in Mechanical Engineering from the University of Dayton.

Niall is the co-founder and serves as Chief Intellectual Property Officer of Carlsmed and Secretary on the Board of Directors.

As a seasoned professional in the spine industry, Niall brings valuable experience from technology leadership roles at well-established companies such as Alphatec Spine, Ellipse Technologies, NuVasive, and J&J DePuy Synthes Spine.

Niall earned a J.D. from Suffolk University and an M.S. and B.S. degree in Biomedical Engineering from Case Western Reserve University.

Jon is a General Partner at U.S. Venture Partners. He serves as a Board Member at Edgewise Therapeutics, Inari Medical, Silverback Therapeutics, Cleave Therapeutics, HealthJoy, Okami Medical, Omada Health, Nuvaira, Ribon Therapeutics, Route 92 Medical and Sparrow Pharmaceuticals. Jon previously served as a Board Member at eFFECTOR Therapeutics, Lutonix, Microvention, OncoMed Pharmaceuticals, Sequent Medical and Proteolix.

Prior to U.S. Venture Partners, he was an Assistant Professor of Neurology and Director of the Neurology-Neurosurgery Special Care Unit at Cornell Medical Center.

Jon earned an M.D. from the University of Florida College of Medicine, an M.B.A. from Columbia University, and an A.B. in Economics from Dartmouth College.

Robert is a General Partner and Head of Healthcare who leads venture and growth investments at B Capital in the sector. Robert and his team have led investments in Hotspot Therapeutics, Lively, Aetion, Oncomyx, and Triumvira OR. He currently serves as a Board Director or Board Observer at Hotspot Therapeutics, Lively, Aetion, Oncomyx, and Triumvira. Previously, he served as a Board Director or Observer at Impel NeuroPharma, Silk Road Medical, TigerConnect, Avalyn Pharma, Neocis, Telcare, VisitPay, IntersectENT, iRhythm, Omada, TalkSpace, and iCardiac.

Prior to his career in venture capital, Robert led Marketing and Business Development at Hansen Medical.

Robert earned an M.D. from Harvard University, an M.B.A. from Harvard Business School, an M.S. in Systems Engineering from the Massachusetts Institute of Technology, and an M.A. in International Relations from Kings College London.

Phil serves as Senior Advisor at US Venture Partners, following 20 years as a managing general partner of the firm. He previously served as a Board Member at Aerogen, Aptus Endosystems, CardioThoracic Systems, CardioVascular Imaging Systems, CoCensys, Compugen, Dotomi, FemRx, HeartFlow, La Jolla Pharmaceuticals, Penederm, 3Dfx Interactive, RelayHealth, SentreHEART, Simpirica Spine, Synarc, St. Francis Medical Technologies, The Immune Response Corporation, Vical, Xoma and Zoran.

Prior to US Venture Partners, Phil was the President and CEO of Oximetrix. He also served on the Board of Trustees of Cornell University and was the Chair of eCornell for nearly 20 years.

Phil earned an M.B.A. from Harvard Business School, an M.S. in Engineering Physics from George Washington University, and a B.M.E. from Cornell University.

Kevin is a Board Member at Intrinsic Therapeutics, Miach Orthopaedics, Razor Medical, FzioMed, Shoulder Innovations, and Moximed.

He previously served on the Board at Rotation Medical, Ceterix, and Pivot Medical. Kevin is the former CEO of St. Francis Medical Technologies, Moximed, as well as past Worldwide President of Johnson & Johnson’s DePuy Orthopedics.

Kevin earned a B.S. in Accounting from West Virginia University.

Kevin is currently a Board Member at Nevro (NVRO), and previously served as a Director of seven publicly traded companies, including Wright Medical Group (WMGI), GenMark Diagnostics (GNMK) and Zeltiq (ZLTQ).

Kevin is a former Senior Vice President and CFO of Advanced BioHealing and served as CFO of NuVasive. Prior to that, he was CFO and COO at ChromaVision Medical Systems (CVSN). Kevin also held several leadership positions at Albert Fisher Group PLC, including CFO and SVP Operations.

Kevin earned a B.S. in Accounting from Rochester Institute of Technology and completed the Executive Program at the UCLA Anderson School of Management.

Paving the Way for the Future of Spinal Fusion Surgery

First company to receive FDA Breakthrough Device Designation for Intervertebral Spine Fusion Technology

2020

July

FDA Breakthrough Device Designation of aprevo®

December

FDA 510(k) clearance of aprevo® Lumbar

2021

February

First in-person aprevo® ALIF procedure

June

First in-person aprevo® LLIF procedure

August

First in-person aprevo® TLIF-O procedure

October

CMS award of NTAP Reimbursement and TPT Payment for aprevo®

2022

August

First in-person aprevo® TLIF-C procedure

October

COMPASS™ personalized spine surgery study begins enrollment

2023

January

First in-person aprevo® ALIF-X procedure

September

FDA grants second Breakthrough Device Designation for Carlsmed Cervical Technology

2024

August

First in-person aprevo® TLIF-CA procedure

November

Carlsmed launches cutting-edge digital production line

December

FDA 510(k) clearance of aprevo® Cervical